Tag:
Avonex
Latest Headlines
Latest Headlines
Biogen Idec secures FDA nod for Avonex delivery accessory
Biogen Idec ($BIIB) gained the FDA's go-ahead this week for a drug delivery advance and dosing change intended to improve how MS patients take Avonex. They are subtle yet significant ways...
Biogen takes European MS marketing in-house with JV buyouts
Biogen Idec ( $BIIB ) is taking its multiple sclerosis marketing in-house. The Massachusetts-based company has bought out the joint-venture partner that had been selling Avonex and Tysabri, forming
Biogen expects MS sales hit from Gilenya
We've heard a lot about Novartis' new multiple sclerosis drug Gilenya, the first oral treatment for the disease. It has hit the ground running, growing sales and grabbing market share just as the
Biogen Idec lengthens shelf life of Avonex
Biogen Idec has succeeded in extending patent protection for its multiple sclerosis drug Avonex to 2026, some 13 years beyond the original patent-expiration date. The IP sleight of hand comes in the
Biogen Idec touts pipeline prospects in review
Biogen Idec rolled out the red carpet to analysts and journalists alike yesterday as it touted its research program and talked up its mid- and late-stage drug prospects. The Boston-based company,
